Cancer

Halberd/Athena GTX Research Promises a Much Brighter Future

Walt Disney once said, "All our dreams can come true if we have the courage to pursue them".JACKSON CENTER, PA…

2 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /…

2 months ago

Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 months ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds…

2 months ago

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European marketLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and…

2 months ago

Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

2 months ago

Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

2 months ago

Cantargia Publishes Interim Report for the First Quarter of 2024

LUND, SE / ACCESSWIRE / May 21, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its…

2 months ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

2 months ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher…

2 months ago